French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure ...

The green light in the US is the first worldwide for Enflonsia ( clesrovimab) and makes the long-acting antibody the first ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season  Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in early ...

French pharma major Sanofi (Euronext: SAN) has started early global shipments of its monoclonal antibody Beyfortus ...

Sanofi (ENXTPA:SAN) has recently announced it will begin shipping Beyfortus in early Q3 2025. This move aims to support healthcare providers ahead of the RSV season. Sanofi's commitment to increasing ...

MSD's Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which ...